Bijuva vs Femoston for Menopausal Hormone Therapy
For a symptomatic postmenopausal woman with a uterus and without contraindications, choose Bijuva (estradiol + micronized progesterone) over Femoston (estradiol + dydrogesterone) based on the superior safety profile of micronized progesterone, particularly regarding cardiovascular and breast cancer risk.
Guideline-Based Recommendation
The 2017 AACE/ACE guidelines explicitly state that "when the use of progesterone is necessary, micronized progesterone is considered the safer alternative" 11. This recommendation directly addresses your choice between these two formulations, as Bijuva contains micronized progesterone while Femoston contains dydrogesterone (a synthetic progestogen).
The 2015 Endocrine Society guidelines recommend that for women with moderate cardiovascular risk, transdermal estradiol combined with micronized progesterone (or another progestogen that does not adversely modify metabolic parameters) should be first-line treatment because these preparations have fewer adverse effects 2.
Key Differentiating Factors
Progestogen Component - The Critical Distinction
Micronized progesterone (in Bijuva) is bioidentical to endogenous progesterone and appears to have:
Dydrogesterone (in Femoston) is a synthetic progestogen that, while generally well-tolerated, lacks the explicit guideline endorsement given to micronized progesterone 67
Cardiovascular Considerations
Recent evidence from 2026 confirms that transdermal estradiol is associated with lower venous thromboembolism risk than oral estrogen, and micronized progesterone may offer additional cardiovascular advantages 4. A 2026 comparative study showed Femoston significantly increased HDL-C (favorable) but also increased triglycerides (less favorable), whereas these lipid changes were not seen with similar regimens 8.
Efficacy Data
Both formulations effectively reduce vasomotor symptoms:
- Bijuva demonstrated statistically significant reductions in both frequency and severity of moderate-to-severe hot flashes at weeks 4 and 12 compared to placebo 9910
- Femoston has extensive literature supporting effective symptom relief and high amenorrhea rates 68
The efficacy is essentially equivalent between the two options.
Clinical Algorithm for Decision-Making
Start with Bijuva (estradiol + micronized progesterone) as first-line unless:
- Patient has specific lipid concerns requiring HDL elevation → Consider Femoston may provide HDL benefit 8
- Patient has hypertriglyceridemia → Avoid Femoston (increases TG); use Bijuva 8
- Patient requires antiandrogenic effects (hirsutism, acne) → Femoston with dydrogesterone may be preferable 8
- Patient has sleep disturbances → Bijuva with micronized progesterone offers additional sleep benefits 5
- Patient has elevated cardiovascular or VTE risk → Strongly favor Bijuva with micronized progesterone 114
Important Caveats
- Both products are FDA-approved and guideline-endorsed for women with a uterus 299
- The AACE explicitly recommends against custom-compounded bioidentical hormones, but Bijuva is FDA-regulated and distinct from compounded products 1110
- Dosing matters: Bijuva comes in 0.5mg/100mg or 1mg/100mg estradiol/progesterone; Femoston has multiple dose options including ultra-low doses 97
- Both require endometrial surveillance if unscheduled bleeding occurs 2
- Annual reassessment of continued need is mandatory 2
Bottom Line
Bijuva is the preferred choice based on the explicit guideline recommendation favoring micronized progesterone as the safer progestogen alternative, particularly for cardiovascular and metabolic safety 11. Femoston remains a reasonable alternative when specific clinical scenarios (HDL optimization, antiandrogenic needs) warrant its use, but it should not be the default first choice given current evidence hierarchy.